Antibodies to CCR2
AssigneesPfizer Inc., Amgen Fremont Inc.
InventorsRonald P. Gladue, Bradley T. Keller, Shinji Ogawa, Arvind Rajpal, Laurie A. Tylaska, Shelley Sims Belouski, Larry L. Green, Meina Liang
Life of this patent
Estimating the term…
Loading patent…
AssigneesPfizer Inc., Amgen Fremont Inc.
InventorsRonald P. Gladue, Bradley T. Keller, Shinji Ogawa, Arvind Rajpal, Laurie A. Tylaska, Shelley Sims Belouski, Larry L. Green, Meina Liang
Estimating the term…
Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, specifically human CCR2, and that may function to inhibit CCR2. Anti-CCR2 antibodies include those which bind to the first and/or second extracellular loops of CCR2. Also provided are human anti-CCR2 antibodies and antigen-binding portions thereof. Isolated heavy and light chain immunoglobulins derived from human anti-CCR2 antibodies and nucleic acid molecules encoding such immunoglobulins are provided. Methods of making human anti-CCR2 antibodies or antigen-binding portions, compositions comprising these antibodies or antigen-binding portions, methods of using the antibodies and antigen-binding portions, and compositions for diagnosis and treatment are provided. Also provided are gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CCR2 antibodies or antigen binding portions thereof.
An isolated human monoclonal antibody or an antigen-binding portion thereof that specifically binds to human CCR2, comprising a heavy chain variable (VH) domain amino acid sequence comprising
An isolated human monoclonal antibody or an antigen-binding portion that specifically binds to CCR2, comprising:
An isolated human monoclonal antibody or an antigen-binding portion thereof that specifically binds to human CCR2, comprising the heavy chain variable (VH) domain amino acid sequence of SEQ ID NO:83 and the light chain variable (VL) domain amino acid sequence of SEQ ID NO:113.
Dependencies are inferred from the claim text.